Perspectivas clínicas de los Neoplasmas Mieloproliferativos
Resumen
Las neoplasias mieloproliferativas son trastornos clonales de células madre hematopoyéticas, caracterizadas por panmielosis, con maduración efectiva. Este trastorno hematológico incluye patologías como la policitemia vera, trombocitemia esencial, leucemia mieloide crónica, leucemia eosinofílica crónica, mielofibrosis primaria y leucemia neutrofílica crónica. Dichos trastornos están vinculados por similitudes morfológicas y propensión a las complicaciones trombóticas y a la transformación leucémica. Estos trastornos comparten alteraciones genéticas, como mutaciones en JAK2, CALR y MPL. El diagnóstico temprano es muy importante para tratamiento adecuado. La identificación genética es la base para poder comprender su patogénesis, pronóstico y responder a terapias dirigidas, mejorando el pronóstico y la calidad de vida.
Descargas
Citas
McMullin MF, Anderson LA. Aetiology of myeloproliferative neoplasms. Cancers. 2020;12(7):1810.
Curto N, Harrison C, McLornan DP. Bone marrow niche dysregulation in myeloproliferative neoplasms. Haematologica. 2020;105(5):1189.
Mesa R, Palmer J, Eckert R, Huberty J. Quality of life in myeloproliferative neoplasms: symptoms and management implications. Hematol Oncol Clin North Am. 2021;35(2):375-390.
Abu-Zeinah K, Saadeh K, Silver R, Scandura J, Abu-Zeinah G. Excess mortality in younger patients with myeloproliferative neoplasms. Leuk Lymphoma. 2023;64(3):725-729.
Marchetti M, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, et al. Second cancers in MPN: Survival analysis from an international study. Am J Haematol. 2020;95:295-301.
Poluben L, Puligandla M, Neuberg D, Bryke CR, Hsu Y, Shumeiko O, et al. Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident. Am J Haematol. 2019;94:62-73.
Jayasuriya N, Kjaergaard A, Pedersen K, Sørensen A, Bak M, Larsen M, et al. Smoking, blood cells and myeloproliferative neoplasms: Meta-analysis and Mendelian randomization of 2·3 million people. Br J Haematol.
Duncombe A, Anderson L, James G, de Vocht F, Fritschi L, Mesa R, et al. Modifiable lifestyle and medical risk factors associated with myeloproliferative neoplasms. Haemasphere. 2020;4:e327.
Van Egeren D, Escabi J, Nguyen M, Liu S, Reilly CR, Patel S, et al. Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2-Mutant Myeloproliferative Neoplasms. Blood (2020) 136(Supplement 1):7–8. doi: 10.1182/blood-2020-141643
Stengel A, Baer C, Walter W, Meggendorfer M, Kern W, Haferlach T, et al. Mutational Patterns and Correlation to Chip-Related Mutations in Hematological Malignancies - A Study on Mutation Frequencies of 122 Genes in 28 Entities Including 3096 Cases. Blood (2020) 136(Supplement 1):37–8. doi: 10.1182/blood-2020-136288
Greenfield G, McMullin MF, Mills K. Molecular pathogenesis of the myeloproliferative neoplasms. J Hematol Oncol. 2021;14:1-18.
Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia. 2021;35(12):3339-51.
Lurlo A, Cattaneo D, Bucelli C, Baldini L. New perspectives on polycythemia vera: from diagnosis to therapy. Int J Mol Sci. 2020;21(16):5805.
Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(9):1465-1487.
Gangat N, Szuber N, Tefferi A. JAK2 unmutated erythrocytosis: 2023 update on diagnosis and management. Am J Hematol. 2023;98(6):965-981.
Accurso V, Santoro M, Raso S, Contrino AD, Casimiro P, Di Piazza F, et al. Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study. Hematol Rep. 2019;11(4):8281.
Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho T, et al. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clin Proc. 2019 Apr;94(4):599-610. doi: 10.1016/j.mayocp.2018.08.022.
Smith CJ, Thomas JW, Ruan G, et al. A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: comparison with data from a Mayo Clinic single institutional series. Am J Hematol. 2021;96(12):E464-E468.
Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia. 2021;35(12):3339-51.
Ronner L, Podoltsev N, Gotlib J, Heaney ML, Kuykendall AT, O’Connell C, et al. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood. 2020;135:1696–703.
Quintero Sierra Y, Hernández Veiries Y, Concepción Fernández Y, Hernández Padrón C, Macia Pérez I, Romero González A. Trombocitemia esencial en pacientes adultos: 10 años de experiencia. Rev Cubana Hematol Inmunol Hemoter. 2023;39.
Petruk C, Mathias J. The Myeloproliferative Neoplasm Landscape: A Patient's Eye View. Adv Ther. 2020;37(5):2050-70.
Barrios A, Davila D, Fountain E, Cheng L, Verstovsek S, Rojas-Hernandez CM. Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis. Sci Rep. 2022;12(1):4674.
Cuthbert D, Stein BL. Polycythemia vera-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. J Blood Med. 2019;10:359-71.
Ahlstrand E, Samuelsson J, Lindgren M, Pettersson H, Liljeholm M, Ravn-Landtblom A, et al. Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up. Eur J Haematol. 2020;104(3):271-8.
Gerds AT, Mesa R, Burke JM, Grunwald MR, Stein BL, Squier P, et al. Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL. Blood. 2024;143(16):1646-55.
Latifi Y, Moccetti F, Wu M, Xie A, Packwood W, Qi Y, et al. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood. 2019;133(14):1597-1606. Blood (2019) 133 (14): 1597–1606.
Kantarjian HM, Deininger MW, Abruzzese E, Apperley J, Cortes JE, Chuah C, et al. Efficacy and safety of ponatinib (PON) in patients with chronic-phase chronic myeloid leukemia (CP-CML) who failed one or more second-generation (2G) tyrosine kinase inhibitors (TKIs): analyses based on PACE and Optic. Blood. 2020;136:43-4.
Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, et al. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019;3(6):851-861.
Januzzi JL, Garasic J, Kasner S, McDonald V, Petrie MC, Seltzer J, et al. An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia.
Cortes J. How to manage CML patients with comorbidities. Hematology 2020, the American Society of Hematology Education Program Book. 2020;2020(1):237-42.
Gambacorti-Passerini C, Coutre PL, Piazza R. The role of bosutinib in the treatment of chronic myeloid leukemia. Future Oncol. 2020;16(2):4395-4408.
Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138(21):2042-2050.
Johnstone J, Thomas L. Chronic Eosinophilic Leukemia Presenting as Asthma. In: TP7. TP007 PULMONARY AND ALLERGY CASE REPORTS. American Thoracic Society; 2021. p. A1366-A1366.
Papadakis S, Liapis I, Papadhimitriou SI, Spanoudakis E, Kotsianidis I, Liapis K. Approach to Acute Myeloid Leukemia with Increased Eosinophils and Basophils. J Clin Med. 2024;13(3):876.
Robak T, Puła A, Braun M, Robak E. Extramedullary and extranodal manifestations in chronic lymphocytic leukemia–an update. Ann Hematol. 2024;103(9):3369-3383.
Morales-Camacho RM, Caballero-Velázquez T, Borrero JJ, Bernal R, Prats-Martín C. Hematological Neoplasms with Eosinophilia. Cancers. 2024;16(2):337.
Kim AS, Pozdnyakova O. SOHO State of the Art Updates and Next Questions|Myeloid/Lymphoid Neoplasms with Eosinophilia and Gene Rearrangements: Diagnostic Pearls and Pitfalls. Clin Lymphoma Myeloma Leuk. 2022;22:643-651
Mittal N, Gupta R, Rahman K, Singh P, Panda I, Nityanand S. A case of paraneoplastic hyperleukocytosis closely mimicking chronic neutrophilic leukemia. J Cancer Res Ther. 2020;16(1):186-8.
Rumi, E., Trotti, C., Vanni, D., Casetti, I. C., Pietra, D., & Sant’Antonio, E. (2020). The genetic basis of primary myelofibrosis and its clinical relevance. International Journal of Molecular Sciences, 21(23), 8885.
Courtier F, Garnier S, Carbuccia N, Guille A, Adélaide J, Chaffanet M, et al. Targeted molecular characterization shows differences between primary and secondary myelofibrosis. Genes Chromosomes Cancer. 2020;59(1):30-9.
Prakash S, Orazi A. How I diagnose primary myelofibrosis. Am J Clin Pathol. 2022;157(4):518-30.
Guy A, Bidet A, Ling C, Caumont C, Boureau L, Viallard JF, Parrens M. Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis. Virchows Arch. 2021;479(4):755-64.
Tefferi A, Gangat N, Pardanani A, Crispino JD. Myelofibrosis: genetic characteristics and the emerging therapeutic landscape. Cancer Res. 2022;82(5):749-63
Derechos de autor 2025 Lizbeth Pamela Espinales Oñate , Sophia Alejandra Aguirre Castro, Omar Antonio Rodriguez Alvarez, Ana Cristina Oscuez Mayorga
Esta obra está bajo licencia internacional Creative Commons Reconocimiento 4.0.
.png)
.png)
1.png)
